Thursday, November 23, 2017
UC's CRISPR case has not wilted
“We are pleased that the briefing is now complete and that the court can now proceed to hear and decide the appeal,” commented Eric Rhodes, CEO of ERS. “One of the important questions in this case is whether Broad’s deployment of conventional techniques for using bacterial systems in eukaryotic cells was an obvious aspect of UC’s core CRISPR-Cas9 invention. Our side is adamant in our belief that this is the case.”...
Full release at http://www.businesswire.com/news/home/20171122005366/en/ERS-Genomics-Update-U.S.-Patent-Interference-Process